Huons files new PE drug application for marketing approval with KFDA

Published: 2012-09-04 06:56:00

Updated: 2012-09-04 06:56:00

Huons announced last Friday that it has filed a marketing application for its new oral premature ejaculation (PE) drug (clomipramine HCl) with the Korea Food and Drug Administration.

Jointly developed by CTC Bio, clomipramine is a tricylic antidepresasnt to treat premature ejaculation

“The ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK